Pfizer Canada president Cole Pinnow said the four occurrences of facial paralysis among close to 22,000 subjects in U.S. clinical trials who received the Pfizer-BioNTech COVID-19 vaccine represented a frequency not above what is expected in the general population.
.png?crop=1.777xh:h;*,*&downsize=510px:*)
